Results 31 to 40 of about 140,938 (293)

KRAS-G12C in the crosshairs [PDF]

Nature Reviews Cancer, 2019
Two papers report the discovery and preclinical analyses of two different covalent inhibitors of KRAS-G12C (AMG 510 and MRTX849) as well as the first data on the efficacy of these inhibitors in cancer patients.
openaire   +2 more sources

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS

Сибирский онкологический журнал, 2016
Mutations in KRAS and BRAF genes in 80 colorectal cancer (CRC) samples from Russian patients were tested using two methods: 1) allele-specific real-time PCR (as-rt PCR) and 2) wild-type blocking PCR with Sanger sequencing (WTBS).
E. E. Pisareva, L. N. Ljubchenko, S. P. Kovalenko, V. A. Shamanin   +3 more
doaj   +1 more source

KRAS: Druggable at Last

The Oncologist, 2023
The approval of adagrasib for non–small cell lung cancer is a milestone in drug development. This commentary highlights the history of the research that led to this breakthrough that will help many patients with KRAS-mutated cancers to live longer and better.
Benjamin O Herzberg, Gulam A Manji
openaire   +2 more sources

Somatic mutation testing: the role in differential diagnosis of thyroid neoplasms [PDF]

Эндокринная хирургия, 2019
Background: In the preoperative diagnosis of thyroid tumors the cytological examination of the material of fine needle aspiration biopsy is the gold standard and serves as the basis for planning of treatment strategy.
Vera A. Kachko, Andrew R. Zaretsky, Vladimir E. Vanushko, Nadezhda M. Platonova, Aleksandr Yu. Abrosimov, Galina V. Semkina   +5 more
doaj   +1 more source

Institutional and Legal Arrangements for the Macro-prudential Supervision Activities of the Financial Stability Committee

Politeja
The article is devoted to the Financial Stability Committee, which bridged the institutional gap that emerged after the 2008 crisis. The purpose of the paper is to analyse its institutional and legal capacity for macro-prudential supervision.
Ireneusz Kraś
doaj   +1 more source

Targeting ST2 expressing activated regulatory T cells in Kras-mutant lung cancer

OncoImmunology, 2020
Oncogenic KRAS-mutant lung cancers remain treatment refractory. A better understanding of the immune response of KRAS-mutant lung cancers is required to facilitate the development of potential therapeutic strategies.
Byung-Seok Kim, Jelita Clinton, Qing Wang, Seon Hee Chang   +3 more
doaj   +1 more source

Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall, Emma N. Harrison, Genevieve C. Kendall   +2 more
wiley   +1 more source

Neolitske risbe v jami Bestažovci na Krasu

Arheološki Vestnik, 2022
Jama Bestažovca je del starega vodoravnega jamskega rova, ki so ga preoblikovali zapolnitve s sedimenti, kraška denudacija in podiranja. Glavni rov Bestažovce je bil do nedavnega povezan s Perkovo pečino, o čemer pričajo arheološki ostanki ...
Andrej Mihevc
doaj   +1 more source

Circular RNA expression landscapes in myelodysplastic neoplasms: Associations with mutational signatures and disease progression

Molecular Oncology, EarlyView.
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge, Morten Tulstrup, Gabriele Todisco, Pedro Moura, Christophe Côme, Jakob Werner Hansen, Jakob Schmidt Jespersen, Balthasar Schlotmann, Maria Creignou, Mette Dahl, Claudia Schöllkopf, Klas Raaschou‐Jensen, Krister Wennerberg, Bo Porse, Joachim Weischenfeldt, Eva Hellström‐Lindberg, Lasse Sommer Kristensen, Kirsten Grønbæk   +17 more
wiley   +1 more source

KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations [PDF]

Genes & Cancer, 2011
KRAS is a potent oncogene and is mutated in about 30% of all human cancers. However, the biological context of KRAS-dependent oncogenesis is poorly understood. Genetically engineered mouse models of cancer provide invaluable tools to study the oncogenic process, and insights from KRAS-driven models have significantly increased our understanding of the ...
Rónán C, O'Hagan, Joerg, Heyer
openaire   +2 more sources